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Heart failure (HF) with preserved ejection fraction (HFpEF) has emerged as a major 
problem of modern cardiology. In contrast to HF with systolic impairment advances 
in management of HFpEF have been humble and there is lack of proven effective 
treatment to improve longevity and reduce disability in such patients. Futility of the 
medications established in systolic HF to help subjects with HFpEF reflects difference 
in the pathophysiological mechanisms of the two forms of HF. Good understanding of 
these mechanisms is essential for discovery of new treatments in the future. 
 
The numbers of endothelial progenitor cells (EPCs) are upregulated in systolic HF 
and their numbers correlate with levels of various cytokines, such as tumor necrosis 
factor-alpha.
1
 However EPCs counts vary depending on the stage of HF with 
relatively higher levels seen in mild or well-controlled disease but the numbers 
decrease progressively in advanced HF stages.
1
 
 
Hypertension is a major cause of HFpEF as opposed to ischemia in systolic HF. 
Diastolic dysfunction and abnormal cardiac stiffness are recognized factors 
predisposing to the development of HFpEF in patients with high blood pressure.
2
 
Hypertension is related to impairment of EPC migratory capacity in vitro. This may 
be partly explained by upregulation of angiotensin II, a molecule shown to reduce 
telomerase activity in EPCs and to accelerate their senescence.
3
  
 
Circulating microparticles have been appreciated as an important component of 
intercellular communication.
4, 5
 They may be involved in more complex regulatory 
pathways due to their capacity to deliver multiple molecules in the same lipid 
envelope and to specifically target particular types of cells using their surface 
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receptors. Patients with hypertension and systolic HF have abnormal levels of 
different types of blood microparticles but data on microparticles in HFpEF are 
scarce. 
 
EPCs are diverse and they embrace cells of different progeny.
6
 Two types of EPCs 
appear to be of particular relevance. ‘Late’ EPCs are extremely scarce in circulation 
and they most likely represent cells resident within the endothelium. When 
appropriately stimulated they have immense proliferative capacity and can give origin 
to endothelia cells per se. However, their assessment is limited but the requirement for 
long-term in vitro culture experiments. The other major type of EPCs are so called 
‘early’ EPCs, which produce numerous endothelial like cells within few days of in 
vitro culture. They have been shown to be predominantly of monocytic origin and 
they contribute to angiogenesis by releasing appropriate cytokines, chemokines, 
growth factors, etc., thus orchestrating mobilization of other cell types and 
modulating activity of the tissue resident cells. Given the monocytic origin of these 
cells they can be assessed by flow cytometry from fresh blood samples. This 
opportunity has been utilized Berezin et al. in their study published in this issue of 
EBioMedicine.
7
 
 
Berezin et al. have demonstrated significant differences in the pattern of circulating 
EPCs and endothelial microparticles in patients with HF with reduced or preserved 
ejection fraction.
7
 The study provides several interesting observations. Among the 
different EPC phenotypes assessed, only CD14+ cells (i.e., cells of monocytic origin) 
were independently associated with HFpEF. This accords with extensive and ongoing 
cardiac remodeling in patients with HFpEF.  
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However detailed relationship between the tested parameters and measures of cardiac 
remodeling and outcomes were beyond the scope of the present study and need to be 
established in the future in prospective trials. Such information is essential to establish 
whether the tested pathways could produce clinically relevant therapeutic targets. 
 
Of interest, in the study by Berezin et al. HFpEF was related to upregulation of 
monocytes with angiogenic phenotypy rather than cells with ‘classical’ 
CD34+CD309+ EPC phenotype.
7, 8
 This fits well in the progressively better-
understood role of a specific monocyte population (i.e., ‘intermediate’ or Mon2 
subset) in pathogenesis and prognostication in several cardiac disorders including HF. 
In fact, this subset has been shown to have highest of all monocytes expression of 
CD309, Tie-2 and a range of other receptors involved in angiogenesis and tissue 
remodeling.
9
 The results obtained by Berezin et al also correspond to recent 
observations that non-monocytic circulating EPCs can in fact be downregulated in 
HFpEF compared to controls without HF thus highlighting the importance of careful 
characterization of specific phenotype of cells assessed under generic term of EPCs.
10
 
 
Berezin et al. show that changes in proportions of certain types of microparticles 
(CD31+ could be shed from both endothelial cells and platelets) and angiogenic 
monocytes are linked to the type of HF.
7
 It is possible that these changes are 
secondary to the degree of the background ischemia or shifts in cardiac and vascular 
hemodynamics associated with particular HF form (for example, increased 
endothelial shear stress in hypertension). However it can also reflect poorly 
understood aspects of endothelial dysfunction. Indeed, whilst the role of endothelial 
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dysfunction is well-established magnitude and nature of endothelial changes in 
HFpEF is less clear. 
 
Extensive experimental work is also warranted to identify and describe the whole 
length of the pathophysiological pathways implicated in the processes mediated by 
angiogenic monocytes and microparticles. This will help to determine the key 
components of the pathways, which will help to modulate them in the desired 
direction. 
 
The study does not answer the question of whether the observed upregulation of 
biomarkers is involved in the development of HFpEF or they reflect a mechanism 
aiming to contrabalance the pathogenic factors or to promote adaptation of the 
cardiovascular system to hemodynamic changes. These questions will need to be 
answered in the future. Overall the study by Berezin and colleagues provides new 
insight in processes differentiating HFpEF and systolic HF and it leads to a string of 
interesting hypotheses to be tested in the future. 
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